Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077709 · ClinicalTrials.gov registry record · Phase 2
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
A Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder, sponsored by IO Biotech.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT05077709: Active Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder, sponsored by IO Biotech.
NCT05077709 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder that is active but no longer recruiting, run by IO Biotech. The registered enrollment target is 63 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077709, a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Bladder, is active but no longer recruiting, sponsored by IO Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Primary Outcome
Confirmed Objective Response Rate according to RECIST v1.1
Conditions Studied
Interventions
- DRUG IO102-IO103 in combination with pembrolizumab
Study Locations (20)
Other
- Hospital Vall d'Hebron - Barcelona
- Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology) - Barcelona
- Hospital Universitari de Girona Doctor Josep Trueta - Girona
- Hospital Universitario Ramon y Cajal - Madrid
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Virgen de la Victoria - Málaga
- Hospital Universitario Virgen Macarena - Seville
- Hospital Clínico Universitario de Valencia - Valencia
- Hospital Clínico Lozano Blesa - Zaragoza
- Velindre Cancer Center - Cardiff
California
- City of Hope - Duarte
- UC Davis Cancer Center - Sacramento
- University of California San Diego - San Diego
Florida
- Mid Florida Hematology and Oncology Center - Orange City
New York
- Montefiore Medical Center - The Bronx
Ohio
- University of Toledo Medical Center - Toledo
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 2 |
What the registry record for NCT05077709 still lists
NCT05077709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (46% lower).
The record links to 3 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which IO102-IO103 in combination with pembrolizumab is the first listed.
NCT05077709 names 20 study sites across 8 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05077709 about?
NCT05077709 is a clinical study titled "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC". A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cance...
What is the current status of trial NCT05077709?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2022-02-14. Estimated completion is 2024-11-30.
What conditions does trial NCT05077709 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder, Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT05077709?
The interventions under investigation include: IO102-IO103 in combination with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT05077709?
This trial is sponsored by IO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077709 being conducted?
This trial has 20 study locations across California, Florida, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05077709's enrollment target sits among peer trials
63 61st of 124 higher than 64 of 124 other Head and Neck Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI